As of Nov 19, 2026, 1 of 1 active firms rate ENTA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ENTA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.48 – $-0.33 · 2 analysts · -4% YoY
Next period, 2 analysts expect Enanta Pharmaceuticals Inc to earn $-0.41 a share (range $-0.48 – $-0.33), versus $-0.42 a year earlier. Full-year consensus is $-2.29, growing to $-2.37 the year after.
REVENUE · NEXT QUARTER
$16.2M
Range $14.5M – $18.0M · 2 analysts · -13% YoY
Revenue is expected to reach $16.2M (range $14.5M – $18.0M), -12.7% year-over-year., rising to $63.7M next year.
Top analysts covering Enanta Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENTA.
#1
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$18.00+119.2% to target
Overall win rate
44%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #171
Buy
$19.00+131.4% to target
Overall win rate
48%
+ Follow
#3
Roy Buchanan
JMP Securities · Rank #176
Buy
$25.00+204.5% to target
Overall win rate
47%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$20.00+143.6% to target
Overall win rate
38%
+ Follow
#5
Roanna Ruiz
SVB Leerink · Rank #513
Neutral
$9.00+9.6% to target
Overall win rate
30%
+ Follow
ENTA stock forecast FAQ
What is ENTA's average 12-month price target?+
The 1 active firms with a live target average $20.00 for Enanta Pharmaceuticals Inc over the next 12 months, ranging from a $20.00 high to a $20.00 low, as of Nov 19, 2026.
Is ENTA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ENTA?+
1 active firms have a recognized rating on Enanta Pharmaceuticals Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ENTA?+
Among analysts who currently cover ENTA, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #168). Their current call is Buy with a $18.00 target.
What is Enanta Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.48 – $-0.33) across 2 analysts. Full-year EPS is projected at $-2.29, rising to $-2.37 the following year.
How much revenue is Enanta Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $16.2M (range $14.5M – $18.0M). Full-year revenue is projected at —, growing to $63.7M next year.
Have analysts been upgrading or downgrading ENTA lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ENTA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENTA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.